OK SB933

Creates the "Right to Try for Individualized Treatments Act" allowing patients with life-threatening or severely debilitating illnesses to access individualized investigational treatments (including gene therapy antisense oligonucleotides and neoantigen vaccines) based on their genetic profile when FDA-approved options are unlikely to prolong life

Eligible patients must have physician attestation of their condition, have considered all FDA-approved treatments, receive a physician recommendation based on genomic analysis, and provide written informed consent documenting risks including potential for worsened symptoms or hastened death

Manufacturers operating within eligible facilities (those with Federalwide Assurance for human subjects protection) may voluntarily provide treatments and may charge patients for manufacturing costs, but are not required to make treatments available

Health plans, third-party administrators, and government agencies are not required to cover costs of treatments or related services, and patients are liable for all expenses unless otherwise contracted with the manufacturer

Grants civil liability immunity to manufacturers and providers acting in good faith, protects health care providers from licensing board actions for recommending treatments, and prohibits state officials from blocking eligible patient access; effective November 1, 2026